PharmaEngine (4162) - Total Assets
Based on the latest financial reports, PharmaEngine (4162) holds total assets worth NT$4.91 Billion TWD (≈ $154.62 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PharmaEngine - Total Assets Trend (2009–2024)
This chart illustrates how PharmaEngine's total assets have evolved over time, based on quarterly financial data. Also see 4162 company net worth for the company's overall valuation and market capitalisation.
PharmaEngine - Asset Composition Analysis
Current Asset Composition (December 2024)
PharmaEngine's total assets of NT$4.91 Billion consist of 99.7% current assets and 0.4% non-current assets. Review PharmaEngine debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 17.0% |
| Accounts Receivable | NT$71.66 Million | 1.2% |
| Inventory | NT$28.38 Million | 0.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how PharmaEngine's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for PharmaEngine for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaEngine's current assets represent 99.7% of total assets in 2024, an increase from 92.8% in 2009.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2024, down from 17.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
PharmaEngine Competitors by Total Assets
Key competitors of PharmaEngine based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
PharmaEngine - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 43.53 | 53.67 | 22.61 |
| Quick Ratio | 43.34 | 53.55 | 22.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$4.78 Billion | NT$3.96 Billion | NT$3.99 Billion |
PharmaEngine - Advanced Valuation Insights
This section examines the relationship between PharmaEngine's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 47.9% |
| Total Assets | NT$5.85 Billion |
| Market Capitalization | $249.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values PharmaEngine's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PharmaEngine's assets grew by 47.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PharmaEngine (2009–2024)
The table below shows the annual total assets of PharmaEngine from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.85 Billion ≈ $184.24 Million |
+47.90% |
| 2023-12-31 | NT$3.95 Billion ≈ $124.57 Million |
-0.32% |
| 2022-12-31 | NT$3.97 Billion ≈ $124.97 Million |
-1.49% |
| 2021-12-31 | NT$4.03 Billion ≈ $126.85 Million |
-4.29% |
| 2020-12-31 | NT$4.21 Billion ≈ $132.54 Million |
+15.47% |
| 2019-12-31 | NT$3.64 Billion ≈ $114.79 Million |
-5.29% |
| 2018-12-31 | NT$3.85 Billion ≈ $121.19 Million |
-6.43% |
| 2017-12-31 | NT$4.11 Billion ≈ $129.52 Million |
+3.83% |
| 2016-12-31 | NT$3.96 Billion ≈ $124.74 Million |
+22.25% |
| 2015-12-31 | NT$3.24 Billion ≈ $102.03 Million |
+9.99% |
| 2014-12-31 | NT$2.94 Billion ≈ $92.77 Million |
+7.31% |
| 2013-12-31 | NT$2.74 Billion ≈ $86.45 Million |
+66.57% |
| 2012-12-31 | NT$1.65 Billion ≈ $51.90 Million |
+159.80% |
| 2011-12-31 | NT$634.07 Million ≈ $19.98 Million |
+565.57% |
| 2010-12-31 | NT$95.27 Million ≈ $3.00 Million |
+127.98% |
| 2009-12-31 | NT$41.79 Million ≈ $1.32 Million |
-- |
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more